Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822092 · ClinicalTrials.gov registry record
Striatal Connectivity and Clinical Outcome in Psychosis
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 196
- Enrollment target
NCT02822092 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 196 participants.
The verdict
NCT02822092 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 196 participants
- Enrollment target
Study Summary
This is an observational neuroimaging treatment study. This study involves examining the neural circuitry of controlled treatment of patients presenting with a first-episode of psychosis with risperidone or aripiprazole. Patients who present for treatment of a first psychotic episode with a schizophrenia spectrum diagnosis and who are eligible to undergo treatment with either risperidone or aripiprazole will be offered participation in the study. Clinical ratings, neuropsychological testing, neuroimaging and EEG will be conducted at baseline. Additionally, subjects will undergo the same assessments at week 12 to determine treatment-related biomarkers. Clinical ratings, including neurocognitive testing, will be conducted by blinded raters at study visits during treatment. Healthy controls (N=50) will also be recruited and scanned twice (12-week interval) to control for effects of time and practice.
Interventions
- DRUG Risperidone or Aripiprazole (patients only)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2016-07 |
| Est. Completion | 2023-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02822092
The ClinicalTrials.gov registry entry for NCT02822092 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risperidone or Aripiprazole (patients only) is the first listed.
NCT02822092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02822092 about?
NCT02822092 is a clinical study titled "Striatal Connectivity and Clinical Outcome in Psychosis". This is an observational neuroimaging treatment study. This study involves examining the neural circuitry of controlled treatment of patients presenting with a first-episode of psychosis with risperidone or aripiprazole. Patients who present for treatment of a first psychotic episode with a schizoph...
What is the current status of trial NCT02822092?
This trial is currently completed. The enrollment target is 196 participants. The study started on 2016-07. Estimated completion is 2023-12.
What interventions are being tested in trial NCT02822092?
The interventions under investigation include: Risperidone or Aripiprazole (patients only) (DRUG).
Who is sponsoring clinical trial NCT02822092?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.